This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2001 Jul 10;104(2):E7.

doi: 10.1161/01.cir.104.2.e7.

Niacin after coronary bypass grafting and for coronary disease prevention

PMID: 11447097
DOI: 10.1161/01.cir.104.2.e7

Comment

Niacin after coronary bypass grafting and for coronary disease prevention

W B Parsons Jr. Circulation. 2001.

. 2001 Jul 10;104(2):E7.

doi: 10.1161/01.cir.104.2.e7.

Author

PMID: 11447097
DOI: 10.1161/01.cir.104.2.e7

No abstract available

PubMed Disclaimer

Comment on

Secondary prevention of coronary heart disease: the role of fibric acids.
Haffner SM. Haffner SM. Circulation. 2000 Jul 4;102(1):2-4. doi: 10.1161/01.cir.102.1.2. Circulation. 2000. PMID: 10880405 No abstract available.
Postscripts from the Post-Coronary Artery Bypass Graft trial: the sustained benefit of more aggressive cholesterol lowering and the enigma of low-dose anticoagulation.
Waters DD, Azar RR. Waters DD, et al. Circulation. 2000 Jul 11;102(2):144-6. doi: 10.1161/01.cir.102.2.144. Circulation. 2000. PMID: 10889122 No abstract available.
Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?
Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N, Bergeron J, Gaudet D, Tremblay G, Prud'homme D, Nadeau A, Després JP. Lemieux I, et al. Circulation. 2000 Jul 11;102(2):179-84. doi: 10.1161/01.cir.102.2.179. Circulation. 2000. PMID: 10889128

Similar articles

Antioxidants blunt high-density lipoprotein response to statin plus niacin therapy.
Kris-Etherton PM. Kris-Etherton PM. Curr Atheroscler Rep. 2001 Nov;3(6):435-6. doi: 10.1007/s11883-001-0032-9. Curr Atheroscler Rep. 2001. PMID: 11602062 No abstract available.
Niacin as a component of combination therapy for dyslipidemia.
Miller M. Miller M. Mayo Clin Proc. 2003 Jun;78(6):735-42. doi: 10.4065/78.6.735. Mayo Clin Proc. 2003. PMID: 12934785 Review.
Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA. Sposito AC, et al. Braz J Med Biol Res. 2001 Feb;34(2):177-82. doi: 10.1590/s0100-879x2001000200004. Braz J Med Biol Res. 2001. PMID: 11175492 Clinical Trial.
The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials.
Sacks FM. Sacks FM. Am J Cardiol. 2001 Dec 20;88(12A):14N-18N. doi: 10.1016/s0002-9149(01)02147-6. Am J Cardiol. 2001. PMID: 11788125 Review.
Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
Scanu AM, Bamba R. Scanu AM, et al. Am J Cardiol. 2008 Apr 17;101(8A):44B-47B. doi: 10.1016/j.amjcard.2008.02.031. Am J Cardiol. 2008. PMID: 18375241 Review.

See all similar articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information